Grifols, S.A. (GRFS) Sees Strong Biopharma Growth Led by Gamunex and Yimmugo

We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Grifols, S.A. (NASDAQ:GRFS) is among the most undervalued stocks.

TheFly reported on May 12 that Deutsche Bank reduced its price target on GRFS from €11 to €10 while reaffirming a Hold rating on the stock.

Earlier on May 7, Grifols, S.A. (NASDAQ:GRFS) reported its results for the first quarter of 2026. The company recorded total revenue of €1.7 billion, reflecting a 3.3% increase on a constant currency basis compared with the prior year. Growth was primarily driven by its Biopharma segment, which advanced 6.8% in constant currency, supported by strong demand for immunoglobulin products. Performance was further aided by the rollout of Biotest’s next-generation IVIG Yimmugo in the U.S. and continued momentum from Gamunex in key U.S. and European markets. These gains were partly offset by weaker pricing in albumin in China and tougher comparisons in Alpha-1 and Specialty Proteins.

Grifols, S.A. (GRFS) Sees Strong Biopharma Growth Led by Gamunex and Yimmugo

The corporation’s Adjusted EBITDA rose to €381 million, up 0.8% in constant currency, with a stable margin of 22.4%. Net profit reached €73 million, representing a 21.9% year-over-year increase. Free cash flow before M&A improved to negative €8 million, while leverage stood at 4.3x and liquidity totaled €1.573 billion, supported by recent refinancing actions that extended maturities and strengthened financial flexibility.

Grifols, S.A. (NASDAQ:GRFS) is a global healthcare company specializing in plasma-derived medicines. Founded in Barcelona in 1909, it provides biopharmaceutical products and medical services in over 110 countries.

While we acknowledge the risk and potential of GRFS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GRFS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Strong Buy Tech Stocks to Invest In Now and 10 Most Widely Held Stocks by Individuals in 2026 .

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1